



Suggested Formula	Lidocaine 1.5%, Nifedipine 0.3% Rectal Ointment (Emulsion, 30 g)	FIN	F 007 217
-------------------	--	-----	-----------

### SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Lidocaine, USP	0.450	g				
Nifedipine, USP	0.090	g				
Polyethylene Glycol 300, NF	0.6	mL				
Medisca AlpaWash™	28.79	g				

### SPECIAL PREPARATORY CONSIDERATIONS

#### Ingredient-Specific Information

**Light sensitive** (protect from light whenever possible):

*Nifedipine*

**Hygroscopic** (protect from moisture whenever possible):

*Polyethylene Glycol 300*

**Narrow Therapeutic Index**

*Lidocaine*

#### Suggested Preparatory Guidelines

Non-Sterile Preparation     Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **12 to 15%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

#### **Lidocaine has a Narrow Therapeutic Index.**

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Lidocaine 1.5%, Nifedipine 0.3% Rectal Ointment (Emulsion, 30 g)	FIN	F 007 217
-------------------	--	-----	-----------

**SUGGESTED PREPARATION (for 30 g)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Lidocaine, USP	0.450	g			
Nifedipine, USP §	0.090	g			
Polyethylene Glycol 300, NF §	0.6	mL			
Medisca Alpa Wash™	28.79	g			

\* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

**Preparatory Instruction**

<b>1. Powder-liquid preparation:</b> A. By geometric addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend:  -Lidocaine -Nifedipine  B. Levigate the fine, homogeneous powder blend (Step 1A) with the Polyethylene Glycol 300.  <u>End result:</u> Homogeneous liquid-like dispersion.
<b>2. Powder-liquid to medium integration:</b> A. Incrementally add the homogeneous liquid-like dispersion (Step 1B) to the Alpa Wash™.  <u>Specifications:</u> Continuously mix, using high-shear mixing techniques.  <u>End result:</u> Homogeneous ointment-like dispersion.
<b>3. Product transfer:</b>  Transfer the final product into the specified dispensing container (see “Packaging Requirements”).



Suggested Formula	Lidocaine 1.5%, Nifedipine 0.3% Rectal Ointment (Emulsion, 30 g)	FIN	F 007 217
-------------------	--	-----	-----------

**SUGGESTED PRESENTATION**

Estimated Beyond-Use Date		Packaging Requirements	
	6 months, as per USP*.		- Tightly closed, light-resistant container. - To be administered with a metered-dose measuring device.
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6 Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	2	Keep out of reach of children.	7 Cap tightly after use.
	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	8 For external use only.
	4	Protect from light.	9 May impair mental and/or physical ability. Use care when operating a car or machinery.
	5	Keep at room temperature (20°C – 23°C).	10 Keep in a dry place.
Pharmacist Instructions	<p><b>Note: This non-sterile formulation, as per USP &lt;3&gt;, should not be applied to an open wound or burned area. If this formulation will be applied to an open wound or burned area, it must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within USP &lt;797&gt;. Also, in consideration of the overall formulation make-up and following the manufacturer's specifications, the suggested method of end-stage sterilization is gamma irradiation. The resulting BUD will be 30 days, as per USP &lt;797&gt;, based on a successful sterility test result.</b></p> <p>Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.</p> <p><b>IMPORTANT:</b> - Small batch is prepared due to inherent potential of systemic toxicity.</p> <ul style="list-style-type: none"> <li>- Limits as to the total amount of product used should be established by a physician.</li> <li>- You should not apply this product to open wounds, areas of skin that are damaged or blistered, deep wounds, or large areas.</li> <li>- Continued application of this product might produce systemic side effects. Advise patient accordingly.</li> </ul>		
Patient Instructions	<p>Contact your pharmacist in the event of adverse reactions.</p> <p><b>IMPORTANT:</b> - Do not cover the site of application.</p> <ul style="list-style-type: none"> <li>- The quantity of API administered is directly dependent on the quantity of product applied.</li> </ul>		

\* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



Suggested Formula	Lidocaine 1.5%, Nifedipine 0.3% Rectal Ointment (Emulsion, 30 g)	FIN	F 007 217
-------------------	--	-----	-----------

## REFERENCES

1.	Ointments, Creams, and Pastes. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fifth Edition</i> . American Pharmaceutical Association; 2016: 317.
2.	Xylocaine Ointment 5%. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2015</i> : 3380.
3.	Adalat XL. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2015</i> : 92.
4.	Polyethylene Glycol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 7<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2012: 585.
5.	Lidocaine. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 1862.
6.	Nifedipine. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 1350.
7.	Lidocaine (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #5535.
8.	Nifedipine (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #6613.
9.	Nifedipine. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2012: 351.
10.	Lidocaine (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 4559.
11.	Nifedipine (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 5064.
12.	Lidocaine. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26<sup>th</sup> Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 196.
13.	Nifedipine. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26<sup>th</sup> Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 734.
14.	USP <795>. <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 617.

**DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.**